Cohort profile: The prospective study on Chinese elderly with multimorbidity in primary care in Hong Kong

Dexing Zhang 1, Regina Wing Shan Sit 1, Carmen Wong 1, Dan Zou 1, Stewart W Mercer 2, Marjorie C Johnston 1,3, Samuel Yeung Shan Wong 1

ABSTRACT
Purpose This is an ongoing prospective cohort aiming to examine the biopsychosocial health profiles and predictors of health outcomes of older patients with multimorbidity in primary care in Hong Kong.
Participants From April 2016 to October 2017, 1077 patients aged 60+ years with at least two chronic diseases were recruited in four public primary care clinics in the New Territories East Region of Hong Kong.
Findings to date After weighting, the patients had 4.1 (1.8) chronic conditions and 2.5 (1.9) medications on average; 37% forgot taking medication sometimes; 71% rated their health as fair or poor; 17% were frail; 73% reported one (21%) or two or more (52%) body pain areas; 62% were overweight/obese; 23% reported chewing difficulty; 18% reported incontinence; 36% had handgrip strength below the cut-off; 10% screened positive in sarcopenia; 17% had mild or severer cognitive impairment; 17% had mild to severe depression; 16% had mild to severe anxiety; 50% had subthreshold to severe insomnia; 28% indicated being lonely; 12% needed help in at least one out of the five daily functions and the EuroQol-5-Dimensions-5-Level index score was 0.81 (0.20) and its Visual Analogue Scale (VAS) score was 67.6 (14.6). In the past 12 months, 17% were hospitalised, 92% attended general outpatient clinics, 70% attended specialist outpatient clinics and 10% used elderly daycare centre services, the median out-of-pocket health cost was HK$1000 (US$150). Female and male patients showed significant differences in many biopsychosocial health aspects.
Future plans With assessments and clinical data, the cohort can be used for understanding longitudinal trajectories of biopsychosocial health profiles of Chinese older patients with multimorbidity in primary care. We are also initially planning cohort studies on factors associated with various health outcomes, as well as quality of life and healthcare use.
Cohort registration number ChiCTR-OIC-16008477

INTRODUCTION
Multimorbidity, defined as patients living with two or more chronic health conditions, is common in primary care. The prevalence is increasing over the last decades as a result of an ageing population and changes in lifestyles, for example, more sedentary lifestyle which have increased the risk of obesity, resulting in a higher risk of developing chronic conditions. 1,2 A recent systematic review suggests that the prevalence of multimorbidity is high among the elderly ranging from 12.9% to 95.1% in different studies.3 Multimorbidity is associated with increased disability and depression, reduced quality of life and higher rates of adverse drug consequences.4 Multimorbidity also leads to increased primary and secondary health service utilisation, especially unplanned healthcare, as well as reduced life expectancy.5 The direct and indirect economic burden associated with multimorbidity is huge.6 The annual healthcare costs were €4096.86 among patients with five or more chronic conditions, which was almost five times more than those who were healthy
in a study in the West of Ireland. It has been estimated that by 2030, 66% of the global disease burden will be due to chronic diseases, with most of the burden occurring in the most populous area—Asia. The economic burden highlights an urgent need for holistic understanding of patients with multimorbidity when searching for cost-effective ways to manage these patients, given that treatment of diseases in isolation can be inefficient, leading to duplication of care and poorer health outcomes.

Studies on multimorbidity have increased in recent years, and a clinical guideline on clinical assessment and management of multimorbidity was developed by the National Institute for Health and Care Excellence in the UK in 2016. However, studies are still needed for the epidemiology and profiles of patients with multimorbidity and their longitudinal outcomes to inform policy-making in different populations including Chinese primary care patients. Most studies on primary care patients with multimorbidity are conducted in western countries such as UK, USA, Australia, Spain and Belgium, and limited research has been conducted on psychological and social problems accompanying with multimorbidity.

Several longitudinal studies of multimorbidity have been conducted in Asian populations, but none of these are of primary care patients. Important knowledge gaps still exist regarding the biopsychosocial health profiles of patients with multimorbidity in primary care among Asian Chinese. Therefore, more studies among Chinese patients with multimorbidity in primary care are needed to advance our understanding for services.

This study focuses on the elderly in Hong Kong, where the population is ageing rapidly. Hong Kong has a population of 7.34 million according to the 2016 census data, with 23.7% aged 60 years or above. The rate was higher than the proportions in 2006 (16.5%) and 2011 (19.5%). In Hong Kong, although there is a large private primary care sector, around 85% of people with chronic conditions are managed in the public primary care setting. Given that the Hong Kong population has the longest life expectancy in the world: (81.7 for men and 87.7 for women in 2017), the ageing population and multimorbidity have brought much burden and challenge to the local healthcare system. To inform healthcare providers and policy-makers in allocating suitable health services for people with multimorbidity in primary care, the present study aimed to study the longitudinal biopsychosocial health profiles and also predictors of health outcomes of Chinese patients with multimorbidity who present to public primary care in Hong Kong.

**COHORT DESCRIPTION**

**Study setting and participants**

This study contains primary care patients from four general outpatient clinics (GOPCs) out of the 10 general outpatient clinics (GOPCs) in the New Territory East Cluster (NTEC), Hong Kong, as permission to recruit from these four clinics was given by the local regulator (the Hospital Authority) during the study period. Each GOPC receives about 450 patients each day. The working hours are generally from 9:00 to 17:00 hours from Monday to Friday with some additional night and weekend sessions. In the most recent Hospital Authority Annual Report 2016–2017, the 10 GOPCs in NTEC provided 972,454 consultations in total in the year of 2015/2016, which consisted of one-third of total GOPC consultations in Hong Kong public health system.

The inclusion criteria of participants were: (1) aged 60 years or above; (2) with two or more chronic diseases confirmed by the medical information in the public clinical management system and patients’ self-report and (3) could speak and understand Chinese. No specific exclusion criteria were adopted. However, as participants needed to respond to questionnaire surveys and health checks, they should be able to access the clinic, sign informed consent by themselves, and understand and answer the research questions.

Patients were first consecutively screened for eligibility by trained research assistants in the waiting areas of the GOPCs. For those who were eligible, they were asked to provide a contact phone number and then were scheduled to visit the study nurse for further assessments. All patients provided informed consent before participation in the study. From April 2016 to October 2017, 1077 eligible patients were recruited and completed the baseline assessments. The baseline assessments were conducted through face-to-face interviews by nurses or a social worker at a university affiliated primary care clinic. The flow chart of recruitment is shown in Figure 1. The sample size allows a margin of error at 3% with a 95% CI. It is also 100% powered to detect a mean difference of 0.5 (assuming SD is 1.0) and 90% powered to detect a

---

**Figure 1** Flow chart of recruitment.
| Assessment                                      | Description                                                                                                                                 |
|------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| **Questionnaire**                               |                                                                                                                                            |
| Use of medication                               | No and duration (0–1 year/2–5 years/>5 years) for antihypertensive, cardiovascular and hypolipidaemic drugs, antidiabetics, antipsychotics and analgesics. |
| Compliance of medication use                    | ‘At times, do you forget to take your prescription medications?’ (no/yes)                                                                    |
| Depression                                      | The 2-item Patient Health Questionnaire (PHQ-2) for depression; The 9-item PHQ (PHQ-9) for those with PHQ-2 ≥3.                                  |
| Anxiety                                         | The 2-item Generalised Anxiety Disorder (GAD-2); The 7-item GAD (GAD-7) for those with GAD-2 ≥3.                                          |
| Loneliness*                                     | The 6-item De Jong Gierveld Loneliness Scale; and one question asking ‘Do you feel lonely? (yes/no)’ (added at a later stage) |
| Insomnia                                        | The 7-item Insomnia Severity Index for those answered yes to the screening question ‘In the past 2 weeks, do you have insomnia? (yes/no)’ |
| Pain                                            | A screening question of ‘In the past year, do you have musculoskeletal pain for at least 3 months’, for those who answered ‘yes, one pain area or ‘yes, two or more pain areas’, Brief Pain Inventory was measured. |
| Physical activity                               | For those were screened positive in pain, Physical Activity Scale for the Elderly was measured.                                               |
| Self-rated health                               | ‘In general, how will you describe your health? (extremely good, very good or good/fair/poor)                                               |
| Community network                               | ‘When you need help, do you have someone who is willing to and able to meet your needs?’ (always/sometimes/never)                            |
| Meaning of existence*                           | One item extracted from the validated reliable Chinese Purpose in Life test: “My personal existence is utterly meaningless and purposeless vs. very meaningful and purposeful”, assessed by a 7-point Likert scale with 1 denoting the lowest level and 7 denoting the highest level of perceived meaning of existence. |
| Use of social media                             | A screening question of ‘In the past 2 weeks, have you ever used the following social media’, for those who answered yes to any of the social media, they were further assessed with importance and comfort of using internet. |
| Oral health*                                    | ‘Do you have any difficulty when biting or chewing foods (even with the use of denture) (yes/no)                                             |
| Incontinence*                                   | ‘Do you have incontinence?’ (yes/occasionally/no)                                                                                           |
| Frailty*                                        | The Edmonton Frail Scale.                                                                                                                   |
| Sarcopenia*                                     | The 5-item Sarcopenia Assessment.                                                                                                            |
| Cognition                                       | Mainly assessed with Montreal Cognitive Assessment Hong Kong version but in an earlier stage, Abbreviated Memory Inventory for Chinese was used. |
| Quality of life                                 | The EQ-5D-5L                                                                                                                                |
| Daily function                                  | Instrumental Activities of Daily Living including ability to use telephone, mode of transportation, shopping, food preparation, ability to handle finances. |
| Use of health services                          | Visits to primary care doctors, specialist outpatient clinics, admission to hospital, use of services in elderly daycare centres and out-of-pocket healthcare cost both in private and public in the past year. |
| Alcohol use                                     | The 3-item Alcohol Use Disorders Identification Test-consumption for those who drank alcohol in the past year.                             |
| Tobacco use                                     | One question asking for current, ex-smoking and non-smoking behaviour.                                                                      |
| Caregiving to somebody else                     | ‘Are you taking care of somebody?’ (yes/no)                                                                                                 |
| Social economic status                          | Age, gender, marriage, living status, employment, receiving of social welfare scheme.                                                      |
| **Physical examination**                        |                                                                                                                                            |
| Blood pressure                                  | Measured twice in 15 min after rest.                                                                                                         |
| Body mass index                                 |                                                                                                                                            |
| Waist circumference                             |                                                                                                                                            |
| Handgrip strength                               | Each hand was measured twice.                                                                                                               |

Continued


**Table 1** Continued

| Assessment | Description |
|------------|-------------|
| **Electronic health record and self-report data** | 43 common chronic conditions in 15 categories including:  
1. Metabolic diseases (hypertension, lipid disorder, diabetes).  
2. Cancer.  
3. Disease of the cardiovascular system (coronary heart disease, stroke/cerebrovascular disease, peripheral vascular disease).  
4. Disease of the respiratory system (COPD, bronchiectasis, asthma, chronic pharyngitis / laryngitis).  
5. Disease of the liver, spleen and gallbladder (gallbladder/spleen disease, viral hepatitis, chronic liver disease).  
6. Disease of the stomach and intestines (dyspepsia and gastritis, diverticular disease of intestine, chronic enteritis; irritable bowel syndrome; constipation).  
7. Disease of the musculoskeletal and connective tissue (chronic pain needing medication control, skeletal and connective tissue inflammation (such as arthritis, gout)).  
8. Disease of the genitourinary system (chronic kidney disease (nephritis), prostatitis, benign prostatic hyperplasia).  
9. Disease of the ear, nose and throat (chronic rhinitis, deafness/tinnitus).  
10. Disease of the visual system (glaucoma/cataracts, blindness/ambyopia, diabetic eyes, retinal detachment).  
11. Disease of the skin (eczema, psoriasis).  
12. Disease of the blood (anaemia).  
13. Disease of the nervous system (multiple sclerosis, migraine, epilepsy, Parkinson’s disease).  
14. Mental disorders (schizophrenia/bipolar disorder, depression, anxiety and other stress-related disorders, dementia).  
15. Others. |

| Use of medication | Medication use number and duration (0–1 year/2–5 years/>5 years) for antihypertensive drugs, cardiovascular drugs, cholesterol-lowering drugs, antidiabetics, antipsychotics and analgesics |

*Measures were added at later stages: about 712–995 patients received these measures.  
COPD, Chronic obstructive pulmonary disease; EQ-5D-5L, EuroQoL-5-Dimensions-5-Level.

The measures in the questionnaires included: (1) the number and type of chronic diseases in fifteen categories (a total of 43 chronic conditions) adapted slightly by a group of family physicians and researchers based on chronic conditions employed in previous studies and the International Statistical Classification of Diseases 11. Details can be seen in table 1; (2) depression (screened by the 2-item Patient Health Questionnaire (PHQ-2)); Those with a score of 3 or more (which suggests depression) were further measured by the 9-item PHQ (PHQ-9); (3) anxiety (screened by the 2-item Generalised Anxiety Disorder (GAD-2)). Those with a score of 3 or more (which suggests anxiety) were further measured by the 7-item GAD (GAD-7); (4) loneliness (measured by the 6-item De Jong Gierveld Loneliness Scale) as well as one loneliness question; (5) insomnia (measured by the 7-item Insomnia Severity Index) among those who answered yes to a screening question; (6) pain (measured by the Brief Pain Inventory among those who were screened positive in pain); (7) physical activity (measured by Physical Activity Scale for the Elderly (PASE) among those who were screened positive in pain); (8) frailty (measured by the Edmonton Frail Scale, which was translated and back-translated by experienced bilingual translators); (9) 

**Measures**

The assessments covered a range of measures that are postulated to be potential physical, psychological and social factors associated with multimorbidity. Each complete assessment lasted for about 45–60 min. All the measures were validated and have been widely used or have been used in our previous studies. Information was collected through face-to-face interviews by trained nurses, social workers and research assistants, and additional information of the disease entities, medication use and health service utilisation was confirmed through the review of electronic medical records by nurses. The electronic medical records include patient information and diagnosis, health examinations, medication prescription and health visits to the public health system. The records cover all patients who seek medical services in public health system. It is a medical record system of routine clinical practices with quality ensured by all healthcare professionals including trained doctors, nurses and allied health professionals under Hospital Authority in Hong Kong.

difference of 8% of different rates, with a follow-up rate of 50% ($\alpha=0.05$).
meaning of existence (measured by one question extracted from the validated Chinese Purpose in Life test which was used in a previous study) \(^5\); (10) sarcopenia (measured by the 5-item Sarcopenia Assessment) \(^55,56\); (11) cognition (measured by the Hong Kong Montreal Cognitive Assessment (HK-MoCA) with a score of 22 or above being with normal cognition) \(^57\); (12) alcohol use (screened by one question and then measured by the 3-item Alcohol Use Disorders Identification Test-consumption for those who screened positive); (13) smoking (non-smoker, current smoker, ex-smoker); (14) medication use (number and duration (0–1 year/2–5 years/>5 years) of antihypertensive, cardiovascular and hypolipidaemic drugs, anti-diabetics, antipsychotics and analgesics was checked in electronic medical system, and compliance of medication use was measured by ‘At times, do you forget to take your prescription medications?’ (no/yes)); (15) self-rated health; (16) community network; (17) use of social media (measured by a screening question, and for those who answered yes to any of the social media, they were further assessed on the importance and comfort of using the internet); (17) oral health; (18) incontinence; (19) caregiving to somebody; (20) quality of life (measured by the EuroQoL-5-Dimensions-5-Level (EQ-5D-5L)) \(^58\); (21) daily function (ability to use the telephone, mode of transportation, shopping, food preparation, ability to handle finances were measured); (22) health service utilisation (visits to primary care doctors, specialist outpatient clinics (SOPC), admission to hospital, use of services in elderly daycare centres and out-of-pocket healthcare costs which were not covered by public health system or insurance both in private and public in the past year). In addition, physical examinations included blood pressure, body mass index (BMI), waist circumference and handgrip strength (kg). For blood pressure, two assessments were taken by the nurses. Patients sat for at least 5 min before the first assessment, and they were assessed again 15 min later. Handgrip strength was also assessed twice for each hand. Social economic status, such as age, gender, marriage, living status, employment, receiving of social welfare scheme, was also included. Due to the data collection plan amendments, a few measures were only collected in a subgroup of the patients at a later stage. Summaries of the baseline measures are described in table 1.

The questionnaire was set up in password protected EpiData files in a password-protected computer with quality control. For example, for scale questions with answers on a Likert scale of 1–5, a range of 1–5 and one digit was set up so no other results were allowed during data entry. Additionally, for most data variables, a ‘must enter’ was set up, so that the question could not be missed unless answered or an individual purposely moves to the next question. Checking for missing data was done regularly by experienced researchers and missing data was further collected by nurses through face-to-face interviews, telephone or by checking the electronic medical record system.

**Patient and public involvement**

The research questions and outcome measures were developed based on some most common problems that are widely recognised among elder patients. Patients or the public did not involve in the design of the study, recruitment or conduction of the study. The results of the study would be disseminated to patients once he or she requests so and aggregated data would be reported in project reports and research publications and conferences.

**Findings to date**

Baseline characteristics of the patients in the study are shown in table 2. The weighted data are shown in the bracket beside the unweighted data. The mean age of the study patients was 70 (SD=6.8) (70.5, SD=7.9) years, 70% (55%) were female, 67% (68%) were married, 14% (15%) lived alone, 92% (87%) were retired or housewives, 49% (52%) had 6 years of education or above, 10% (10%) were on the Comprehensive Social Security Assistance scheme which is open for those with a low income, about half used social media in the last 2 weeks, about 18% (15%) provided care to another (such as their spouse or children/grandchildren), 13% (17%) had drank alcohol in the past year and 3% (4%) were current smokers. More female patients lived alone, were retired/housewives, had lower education and more received social security support than male patients (p values <0.05).

After weighting, overall, the mean number of chronic diseases was 4.1 (SD=1.8) and about one in five patients had six or more chronic diseases. The top three chronic conditions were hypertension (75%), dyslipidaemia (46%), and skeletal and connective tissue inflammation (eg, arthritis) (36%). The unweighted and weighted prevalence of comorbidities of the 15 disease categories among the patients is shown in figures 2 and 3, respectively. The unweighted and weighted comorbidities of top 10 prevalent conditions out of the 43 conditions are shown in figures 4 and 5, respectively, with the combination of hypertension and dyslipidaemia being the most common (39%), followed by hypertension and diabetes mellitus (27%), hypertension and skeletal and connective tissue inflammation (eg, arthritis) (26%), dyslipidaemia and diabetes mellitus (21%), hypertension and chronic pain (20%). Information of the rest comorbidities is shown in the figures. Female patients had fewer number of chronic conditions, fewer number of medications in use but poorer self-rated health than male patients (p<0.05). On average, patients took 2.5 (SD=1.9) medications, with 30% taking five or more medications regularly, 36% reported forgot taking medication sometimes.

After weighting, the mean BMI was 24.3 (SD=3.4) with 62% being overweight or obese. Based on the Edmonton Frail Scale, 17% were frail. Ten per cent had sarcopenia, 23% reported chewing difficulty, 17% reported incontinence, 36% had stage one or two hypertension currently according to the physical examination, 38% had their handgrip strength (based on the best outcome
Table 2  Basic characteristics and biopsychosocial health profiles of the elderly with multimorbidity in primary care in Hong Kong

| Characteristics                  | Unweighted rates and analyses | Weighted rates and analyses |
|----------------------------------|-------------------------------|-----------------------------|
|                                  | Female (n=753) | Male (n=324) | P value | Crude total % | Female (n=568) | Male (n=508) | P value | Weighted total % |
| Female                           |               |               |         |               |               |               |         |                  |
| Age (mean, SD)                   | 69.6 (6.6)     | 71.1 (7.1)    | <0.001  | 69.9%         | 70.0 (6.8)     | 71.3 (8.4)    | 70.2 (7.9) | 0.097           | 70.5 (7.9) |
| 60–64                            | 22.8%          | 19.8%         | 0.002   | 22.0%         | 28.8%          | 31.4%         |          | 30.2%           |
| 65–69                            | 35.6%          | 26.5%         |         | 32.9%         | 22.9%          | 25.3%         |          | 24.0%           |
| 70–74                            | 21.8%          | 24.4%         |         | 22.5%         | 12.5%          | 14.5%         |          | 13.4%           |
| 75–79                            | 9.7%           | 16.4%         |         | 11.6%         | 12.1%          | 13.0%         |          | 12.5%           |
| 80 or above                      | 10.1%          | 13.0%         |         | 11.0%         | 23.8%          | 15.7%         |          | 20.0%           |
| Marriage                         | <0.001         |               |         |               | <0.001         |               |         |                  |
| Married                          | 57.9%          | 89.2%         |         | 67.3%         | 54.7%          | 82.9%         |          | 68.1%           |
| Single/divorced/separated        | 11.8%          | 4.3%          |         | 9.6%          | 10.9%          | 9.6%          |          | 10.3%           |
| Widowed                          | 30.2%          | 6.5%          |         | 23.1%         | 34.4%          | 7.5%          |          | 21.7%           |
| No of children (mean, SD)        | 2.5 (1.6)      | 2.5 (1.2)     | 0.409   | 2.52 (1.47)   | 2.7 (1.9)      | 2.4 (1.3)     | 0.013   | 2.53 (1.6) |
| Living alone                     | 16.5%          | 8.3%          | <0.001  | 14.0%         | 18.4%          | 11.9%         | 0.004   | 14.6%           |
| Employment                       |               |               |         |               |               |               |         |                  |
| Retired/housewife                | 96.0%          | 82.4%         | <0.001  | 91.9%         | 95.8%          | 77.5%         | 0.000   | 86.9%           |
| Employed                         | 4.0%           | 17.6%         |         | 8.1%          | 4.2%           | 22.5%         |         | 13.1%           |
| Education (year, mean, SD)       | 7.2 (4.7)      | 8.7 (4.1)     | <0.001  | 7.7 (4.6)     | 6.5 (4.6)      | 8.9 (4.1)     | <0.001  | 7.7 (4.5) |
| Year of education ≥6 years       | 46.8%          | 59.5%         | 0.001   | 49.3%         | 40.7%          | 63.2%         | <0.001  | 51.8%           |
| Social security recipient        | 58.1%          | 59.3%         | 0.726   | 58.6%         | 59.8%          | 50.5%         | 0.002   | 55.4%           |
| Comprehensive Social Security Assistance Scheme | 11.4%          | 7.1%          | 0.031   | 10.1%         | 12.3%          | 7.6%          | 0.011   | 10.1%           |
| Fruit voucher                    | 44.7%          | 50.3%         | 0.089   | 46.4%         | 45.5%          | 41.5%         | 0.190   | 43.6%           |
| Disability allowance             | 3.7%           | 3.1%          | 0.604   | 3.5%          | 3.9%           | 3.0%          | 0.426   | 3.5%            |
| Other                            | 0.5%           | 0.3%          | 0.621   | 0.5%          | 0.4%           | 0.3%          | 0.803   | 0.3%            |
| Caregiving to somebody           | 18.9%          | 14.5%         | 0.118   | 17.6%         | 16.8%          | 13.0%         | 0.126   | 15.0%           |
| Alcohol use                      |               |               |         |               |               |               |         |                  |
| Yes, in last 12 months           | 5.4%           | 29.3%         | <0.001  | 12.6%         | 5.2%           | 29.8%         | <0.001  | 16.8%           |
| AUDIT-C†                         |               |               |         |               |               |               |         |                  |
| AUDIT-C positive (≥3)            | 1.4%           | 11.1%         | <0.001  | 4.4%          | 1.5%           | 11.2%         | <0.001  | 6.1%            |
| Smoke                            | <0.001         |               |         |               | <0.001         |               |         |                  |
| Never smoke                      | 97.1%          | 60.5%         |         | 86.1%         | 96.9%          | 60.3%         |         | 79.6%           |
| Smoke                            | 0.8%           | 7.1%          |         | 2.7%          | 0.8%           | 7.2%          |         | 3.8%            |
Table 2  Continued

| Characteristics                              | Unweighted rates and analyses | Weighted rates and analyses |
|----------------------------------------------|-------------------------------|----------------------------|
|                                              | Female (n=753) | Male (n=324) | P value | Crude total % | Female (n=568) | Male (n=508) | P value | Weighted total % |
| Self-rated health                            |                 |               |         |              |                 |               |         |                  |
| Excellent/very good/good                     | 26.0%           | 34.7%         | <0.001  | 28.5%        | 26.8%           | 32.7%         | 0.001   | 29.5%             |
| Fair                                         | 59.5%           | 58.4%         |         | 59.2%        | 58.6%           | 60.1%         |         | 59.3%             |
| Poor                                         | 14.6%           | 6.9%          |         | 12.3%        | 14.7%           | 7.2%          |         | 11.2%             |
| No of chronic conditions (mean, SD)          |                 |               |         |              |                 |               |         |                  |
| 2 diseases                                   | 4.0 (1.7)       | 4.3 (1.9)     | 0.004   | 4.1 (1.8)    | 4.0 (1.7)       | 4.3 (1.9)     | 0.026   | 4.1 (1.8)         |
| 3 diseases                                   | 21.4%           | 15.4%         | 0.003   | 19.6%        | 22.6%           | 16.0%         | 0.019   | 19.4%             |
| 4 diseases                                   | 25.5%           | 28.7%         |         | 26.5%        | 25.1%           | 29.8%         |         | 27.3%             |
| 5 disease                                    | 21.0%           | 17.0%         |         | 19.8%        | 19.5%           | 16.1%         |         | 17.9%             |
| 6+ disease                                   | 15.0%           | 13.0%         |         | 14.4%        | 14.8%           | 12.7%         |         | 13.8%             |
| Chronic conditions by category               |                 |               |         |              |                 |               |         |                  |
| Metabolic diseases                           | 82.2%           | 86.7%         | 0.066   | 83.6%        | 83.8%           | 85.5%         | 0.449   | 84.6%             |
| Cancer                                       | 7.3%            | 13.0%         | 0.003   | 9.0%         | 7.0%            | 11.6%         | 0.009   | 9.2%              |
| Cardiovascular diseases                      | 13.4%           | 24.7%         | <0.001  | 16.9%        | 14.5%           | 24.1%         | <0.001  | 19.0%             |
| Respiratory disease                          | 6.1%            | 9.8%          | 0.043   | 7.2%         | 6.4%            | 9.9%          | 0.039   | 8.1%              |
| Liver disease                                | 9.3%            | 10.2%         | 0.649   | 9.6%         | 9.3%            | 10.8%         | 0.439   | 10.0%             |
| Gastrointestinal disorders                   | 28.0%           | 23.8%         | 0.148   | 26.7%        | 27.7%           | 23.2%         | 0.093   | 25.5%             |
| Musculoskeletal disorders                    | 65.2%           | 48.8%         | <0.001  | 60.3%        | 65.5%           | 49.8%         | <0.001  | 58.1%             |
| Thyroid disease                              | 9.7%            | 1.9%          | <0.001  | 7.3%         | 9.2%            | 1.9%          | <0.001  | 5.7%              |
| Renal disease                                | 2.3%            | 33.3%         | <0.000  | 11.6%        | 2.1%            | 31.7%         | <0.001  | 16.1%             |
| ENT                                          | 8.9%            | 9.3%          | 0.849   | 9.0%         | 8.8%            | 9.6%          | 0.645   | 9.2%              |
| Eye                                          | 27.9%           | 22.5%         | 0.067   | 26.3%        | 29.1%           | 20.5%         | 0.001   | 25.0%             |
| Skin                                         | 9.3%            | 9.9%          | 0.765   | 9.5%         | 9.0%            | 10.5%         | 0.401   | 9.7%              |
| Anaemia                                      | 3.1%            | 2.8%          | 0.806   | 3.0%         | 3.0%            | 2.8%          | 0.867   | 2.9%              |
| Neurological disease                         | 0.7%            | 1.2%          | 0.346   | 0.8%         | 0.5%            | 1.3%          | 0.175   | 0.9%              |
| Mental disorders                             | 16.7%           | 10.2%         | 0.005   | 14.8%        | 16.4%           | 11.2%         | 0.015   | 14.0%             |
| Use of medication                            |                 |               |         |              |                 |               |         |                  |
| Antihypertensive drugs (mean, SD)            | 1.0 (0.9)       | 1.2 (0.9)     | 0.082   | 1.1 (0.9)    | 1.1 (0.9)       | 1.1 (0.9)     | 0.431   | 1.1 (0.9)         |
| Percentage of patients who use               | 69.1%           | 75.3%         | 0.038   | 70.9%        | 71.3%           | 74.0%         | 0.326   | 72.5%             |
| Cardiovascular drugs (mean, SD)              | 0.2 (0.5)       | 0.3 (0.6)     | <0.001  | 0.2 (0.5)    | 0.2 (0.5)       | 0.3 (0.7)     | 0.024   | 0.24 (0.6)        |
| Characteristics                          | Female (n=753) | Male (n=324) | P value | Crude total % | Female (n=568) | Male (n=508) | P value | Weighted total % |
|------------------------------------------|----------------|--------------|---------|---------------|----------------|--------------|---------|-----------------|
| Percentage of patients who use           | 11.8%          | 22.8%        | <0.001  | 15.1%         | 12.7%          | 21.8%        | <0.001  | 17.0%           |
| Antidiabetics (mean, SD)                 | 0.4 (0.7)      | 0.5 (0.8)    | 0.0195  | 0.4 (0.8)     | 0.3 (0.7)      | 0.5 (0.8)    | 0.029   | 0.4 (0.7)       |
| Percentage of patients who use           | 22.6%          | 31.8%        | 0.001   | 25.4%         | 22.1%          | 31.9%        | <0.001  | 26.7%           |
| Cholesterol-lowering drugs (mean, SD)    | 0.4 (0.5)      | 0.5 (0.5)    | 0.005   | 0.4 (0.5)     | 0.4 (0.5)      | 0.5 (0.5)    | 0.004   | 0.4 (0.5)       |
| Percentage of patients who use           | 38.8%          | 48.2%        | 0.004   | 41.6%         | 37.5%          | 48.4%        | <0.001  | 42.7%           |
| Antipsychotics (mean, SD)                | 0.2 (0.8)      | 0.1 (0.5)    | 0.038   | 0.2 (0.7)     | 0.2 (0.8)      | 0.1 (0.5)    | 0.035   | 0.2 (0.7)       |
| Percentage of patients who use           | 11.7%          | 7.4%         | 0.035   | 10.4%         | 11.1%          | 7.7%         | 0.055   | 9.5%            |
| Analgesics (mean, SD)                    | 0.1 (0.5)      | 0.1 (0.4)    | 0.875   | 0.1 (0.5)     | 0.1 (0.5)      | 0.1 (0.4)    | 0.929   | 0.1 (0.4)       |
| Percentage of patients who use           | 10.5%          | 10.8%        | 0.005   | 10.6%         | 9.8%           | 10.2%        | 0.833   | 10.0%           |
| Total nor of medication (mean, SD)       | 2.3 (1.9)      | 2.7 (1.9)    | 0.001   | 2.4 (1.9)     | 2.3 (1.9)      | 2.6 (1.9)    | 0.025   | 2.5 (1.9)       |
| % forgetting taking medication (n=995)    | 38.4%          | 34.0%        | 0.196   | 37.1%         | 36.3%          | 34.8%        | 0.640   | 35.6%           |
| Oral health problem (n=992)              | 25.3%          | 20.6%        | 0.119   | 23.9%         | 24.8%          | 20.5%        | 0.104   | 22.8%           |
| Incontinence (n=992)                     |                |              | 0.004   | <0.001        |                |              |         | 81.5%           |
| No                                       | 77.0%          | 86.3%        | 79.7%   | 76.9%         | 86.6%          | 81.5%        |         |                 |
| Occasionally                             | 21.3%          | 12.7%        | 18.8%   | 20.3%         | 12.7%          | 16.7%        |         |                 |
| Yes                                      | 1.7%           | 1.0%         | 1.5%    | 2.8%          | 0.7%           | 1.8%         |         |                 |
| Pain                                     |                |              | 0.000   | <0.001        |                |              |         |                 |
| Musculoskeletal pain for at least 3 months in the past year |                |              | 0.000   | <0.001        |                |              |         |                 |
| No                                       | 19.1%          | 37.7%        | 24.9%   | 18.7%         | 37.4%          | 27.5%        |         |                 |
| Yes, one pain area                       | 19.7%          | 23.8%        | 10.9%   | 18.7%         | 23.6%          | 21.0%        |         |                 |
| Yes, two or more pain areas              | 61.2%          | 38.6%        | 64.3%   | 62.7%         | 39.0%          | 51.5%        |         |                 |
| Brief Pain Inventory (BPI)†              |                |              |         |               |                |              |         |                 |
| Interference (n=809)                     | 4.6 (1.9)      | 4.1 (1.9)    | <0.001  | 4.5 (1.9)     | 4.7 (2.0)      | 4.1 (1.9)    | <0.001  | 4.4 (2.0)       |
| Severity (n=810)                         | 2.9 (2.2)      | 2.2 (1.8)    | <0.001  | 2.7 (2.1)     | 2.9 (2.2)      | 2.2 (1.8)    | <0.001  | 2.6 (2.1)       |
| Physical Activity Scale for the Elderly (PASE) (n=809)‡ |                |              |         |               |                |              |         |                 |
| Mean (SD)                                | 77.4 (34.9)    | 89.1 (61.5)  | <0.001  | 80.3 (43.4)   | 74.7 (36.1)    | 95.7 (67.3)  | <0.001  | 83.3 (52.2)     |
| Sarcopenia (mean, SD) (n=719)$§          | 1.5 (1.8)      | 0.7 (1.3)    | <0.001  | 1.2 (1.5)     | 1.7 (1.8)      | 0.7 (1.2)    | <0.001  | 1.2 (1.6)       |
| Positive (≥4)                            | 11.0%          | 5.7%         | 0.019   | 9.3%          | 15.5%          | 5.1%         | <0.001  | 10.4%           |
| Negative (0–3)                           | 89.0%          | 94.3%        | 90.7%   | 84.5%         | 94.9%          | 89.6%        |         |                 |
| Cognition                               ¶ |                |              |         |               |                |              |         |                 |
| AMIC (mean, SD) (n=337)                  | 2.2 (1.7)      | 1.7 (1.6)    | 0.035   | 2.1 (1.7)     | 2.1 (1.7)      | 1.6 (1.6)    | 0.038   | 1.9 (1.7)       |

Continued
Table 2  Continued

| Characteristics                      | Unweighted rates and analyses | Weighted rates and analyses |
|--------------------------------------|------------------------------|-----------------------------|
|                                      | Female (n=753) | Male (n=324) | P value | Crude total % | Female (n=568) | Male (n=508) | P value | Weighted total % |
| AMIC Positive % (≥3)                 | 40.6%          | 27.3%         | 0.027   | 37.1%         | 39.3%          | 24.7%         | 0.007   | 33.3%          |
| HK-MOCA (n=785)                     | 24.7 (4.3)     | 25.4 (3.2)    | 0.026   | 24.9 (4.0)    | 24.0 (4.8)     | 25.5 (3.1)    | <0.001  | 24.7 (4.1)     |
| HK-MOCA Abnormal % (<22)            | 17.5%          | 12.6%         | 0.080   | 15.9%         | 23.0%          | 10.5%         | <0.001  | 16.9%          |
| Depression                           |                |                |         |               |                |                |         |                |
| PHQ-2                                |                |                |         |               |                |                |         |                |
| Screen (-) (<3)                     | 78.1%          | 88.3%         | <0.001  | 81.2%         | 77.8%          | 87.6%         | <0.001  | 82.4%          |
| Screen (+) (≥3)                     | 21.9%          | 11.7%         |         | 18.9%         | 22.2%          | 12.4%         |         | 17.6%          |
| PHQ-9 (mean, SD)**                  | 11.4 (4.3)     | 10.5 (4.5)    | 0.274   | 11.2 (4.4)    | 11.4 (4.2)     | 10.4 (4.3)    | 0.179   | 11.0 (4.3)     |
| Mild (5–9)                           | 8.8%           | 4.3%          |         | 7.4%          | 8.6%           | 4.8%          |         | 6.8%           |
| Moderate (10–14)                    | 7.3%           | 4.9%          |         | 6.6%          | 8.2%           | 5.4%          |         | 6.9%           |
| Moderately severe (15–19)           | 4.2%           | 1.2%          |         | 3.3%          | 4.0%           | 1.2%          |         | 2.7%           |
| Severe (20+)                        | 1.3%           | 0.9%          |         | 1.2%          | 1.2%           | 0.8%          |         | 1.0%           |
| Anxiety                              |                |                |         |               |                |                |         |                |
| GAD-2 (≥3) (mean, SD)               | 1.4 (1.5)      | 0.8 (1.1)     | <0.001  | 1.2 (1.5)     | 1.4 (1.6)      | 0.8 (1.1)     | <0.001  | 1.1 (1.4)      |
| Screen (-) (<3)                     | 79.7%          | 91.1%         | <0.001  | 83.0%         | 79.5%          | 90.9%         | <0.001  | 84.9%          |
| Screen (+) (≥3)                     | 20.3%          | 9.0%          |         | 17.0%         | 20.5%          | 9.1%          |         | 15.1%          |
| GAD-7 (mean, SD)††                  | 10.8 (3.9)     | 9.8 (3.7)     | 0.182   | 10.7 (3.9)    | 10.9 (3.9)     | 10.1 (3.6)    | 0.294   | 10.7 (3.8)     |
| Mild (5–9)                           | 0.9%           | 0.3%          |         | 0.7%          | 0.7%           | 0.2%          |         | 0.5%           |
| Moderate (10–14)                    | 6.9%           | 4.6%          |         | 6.2%          | 8.5%           | 5.0%          |         | 6.8%           |
| Moderately Severe (15–19)           | 9.6%           | 3.4%          |         | 7.7%          | 10.1%          | 4.4%          |         | 7.4%           |
| Severe (20+)                        | 2.9%           | 0.6%          |         | 2.2%          | 3.6%           | 0.6%          |         | 2.2%           |
| Insomnia                             |                |                |         |               |                |                |         |                |
| Insomnia in the past 2 weeks        |                |                | 0.030   |               |                | 0.086         |         |                |
| No                                   | 31.5%          | 28.3%         |         | 33.5%         | 32.2%          | 37.2%         |         | 34.6%          |
| Yes                                  | 68.5%          | 61.7%         |         | 66.5%         | 67.8%          | 62.8%         |         | 65.4%          |
| ISI (n=716) (mean, SD)†              | 12.0 (5.1)     | 10.2 (4.6)    | <0.001  | 11.5 (5.0)    | 11.9 (5.1)     | 10.1 (4.5)    | <0.001  | 11.1 (4.9)     |
| No clinically significant insomnia (0–7) | 13.7%       | 18.2%         |         | 15.0%         | 14.2%          | 18.8%         |         | 16.4%          |
| Subthreshold insomnia (8–14)         | 31.1%          | 29.0%         |         | 30.5%         | 31.0%          | 29.7%         |         | 30.4%          |
| Clinical insomnia, moderate severity (15–21) | 22.2%       | 14.2%         |         | 19.8%         | 22.1%          | 15.0%         |         | 18.8%          |
| Clinical insomnia, severe (22–28)    | 1.6%           | 0.3%          |         | 1.2%          | 1.5%           | 0.3%          |         | 0.9%           |
| Meaning (0–7) (n=544)                | 4.8 (1.2)      | 5.0 (1.1)     | 0.098   | 4.8 (1.2)     | 4.7 (1.3)      | 5.0 (1.1)     | 0.022   | 4.9 (1.2)      |

Continued
| Characteristics                                                | Unweighted rates and analyses | Weighted rates and analyses |
|---------------------------------------------------------------|------------------------------|-----------------------------|
|                                                               | Female (n=753) | Male (n=324) | P value | Crude total % | Female (n=568) | Male (n=508) | P value | Weighted total % |
| **Loneliness (n=741)**                                        |                 |               |         |               |               |               |         |                  |
| One question (yes/no)                                        |                 |               | 0.009   | 0.128         |               |               |         |                  |
| No                                                            | 68.0%          | 77.1%         | 0.090   | 69.8%         | 74.6%         | 0.063         | 72.2%   |                  |
| Yes                                                           | 32.1%          | 22.9%         | 0.275   | 30.2%         | 25.4%         | 0.279         | 27.9%   |                  |
| **De Jong Gierveld Loneliness Scale**                         |                 |               |         |               |               |               |         |                  |
| Total loneliness score (mean, SD)                            | 1.8 (1.9)       | 1.6 (1.7)     | 0.121   | 0.7 (1.2)     | 1.8 (1.8)     | 1.6 (1.7)     | 0.309   | 1.7 (1.8)        |
| Emotional loneliness score (mean, SD)                         | 1.0 (1.1)       | 0.9 (1.0)     | 0.156   | 1.6 (1.8)     | 0.9 (1.0)     | 0.9 (1.0)     | 0.566   | 0.9 (1.0)        |
| Social loneliness score (mean, SD)                            | 0.8 (1.3)       | 0.7 (1.2)     | 0.121   | 0.9 (1.0)     | 0.8 (1.3)     | 0.7 (1.3)     | 0.350   | 0.8 (1.3)        |
| **Social support (can count on someone willing and able to meet your needs)** | 0.083 | 0.146 |         |                  |               |               |         |                  |
| Always                                                        | 61.2%          | 66.3%         |         | 61.6%         | 65.8%         |               | 63.5%   |                  |
| Sometimes                                                     | 31.1%          | 30.0%         |         | 31.2%         | 28.6%         |               | 30.0%   |                  |
| Never                                                         | 7.7%           | 4.1%          |         | 6.7%          | 7.3%          | 5.6%          |         | 6.5%             |
| **Use of social media in last 2 weeks**                       |                 |               |         |               |               |               |         |                  |
| Yes                                                           | 52.5%          | 52.1%         | 0.849   | 52.6%         | 46.6%         | 55.8%         | 0.003   | 51.0%            |
| Web                                                           | 20.9%          | 33.6%         | <0.001  | 24.7%         | 18.5%         | 36.5%         | <0.001  | 27.0%            |
| WhatsApp                                                      | 51.4%          | 50.0%         | 0.675   | 51.0%         | 45.9%         | 52.6%         | 0.028   | 49.0%            |
| Facebook                                                      | 15.9%          | 20.4%         | 0.077   | 17.3%         | 14.5%         | 20.7%         | 0.006   | 17.4%            |
| Blog                                                          | 1.7%           | 3.4%          | 0.089   | 2.2%          | 1.3%          | 3.0%          | 0.065   | 2.1%             |
| **E-literacy (n=566)‡‡**                                      |                 |               | 0.931   | 25.0 (12.0)   | 25.5 (11.6)   | 25.4 (12.7)   | 0.953   | 25.4 (12.2)      |
| **Importance of social media (total score: 6–24)**            |                 |               | 0.218   | 11.1 (4.8)    | 11.5 (4.7)    | 10.8 (4.8)    | 0.171   | 11.1 (4.8)       |
| **Comfort of using social media (total score: 3–18)**         |                 |               | 0.975   | 8.2 (4.5)     | 8.3 (4.4)     | 8.3 (4.7)     | 0.878   | 8.3 (4.5)        |
| **Daily function (Percentage of patients needing help or being dependent)** |                 |               |         |               |               |               |         |                  |
| Total                                                         | 8.4%           | 14.8%         | 0.001   | 10.3%         | 10.5%         | 14.3%         | 0.056   | 12.3%            |
| Using telephone                                              | 0.7%           | 1.2%          |         | 0.8%          | 1%            | 1%            |         | 1%               |
| Transportation                                               | 4.7%           | 5.6%          |         | 4.3%          | 5.9%          | 5.4%          |         | 5.7%             |
| Shopping                                                     | 5.7%           | 5.0%          |         | 5.5%          | 7.5%          | 4.8%          |         | 6.2%             |
| Preparing meals                                              | 4.3%           | 12.7%         |         | 6.8%          | 5.5%          | 12.7%         |         | 8.9%             |
| Financial management                                         | 2.9%           | 4.9%          |         | 3.5%          | 4.1%          | 0.9%          |         | 2.6%             |
| **Frailty**                                                  |                 |               |         |               |               |               |         |                  |
| Edmonton Frail Scale (mean, SD) (n=989)§§                    | 3.5 (2.3)       | 3.1 (2.0)     | 0.003   | 3.4 (2.2)     | 3.7 (2.4)     | 3.1 (2.0)     | <0.001  | 3.4 (2.2)        |
### Table 2 Continued

| Characteristics                                      | Female (n=753) | Male (n=324) | P value | Crude total % | Female (n=568) | Male (n=508) | P value | Weighted total % |
|------------------------------------------------------|----------------|--------------|---------|---------------|----------------|--------------|---------|------------------|
| No frailty (0–5)                                     | 80.3%          | 88.3%        | 0.012   | 82.6%         | 77.6%          | 88.7%        | <0.001  | 82.8%            |
| Apparently vulnerable (6–7)                          | 13.7%          | 8.6%         |         | 12.2%         | 13.8%          | 8.7%         |         | 11.4%            |
| Mild frailty (8–9)                                    | 4.7%           | 2.4%         |         | 4.0%          | 6.8%           | 2.0%         |         | 4.6%             |
| Moderate frailty (10–11)                              | 1.3%           | 0.3%         |         | 1.0%          | 1.8%           | 0.2%         |         | 1.1%             |
| Severe frailty (12–18)                                | 0.0%           | 0.33%        |         | 0.1%          | 0.0%           | 0.4%         |         | 0.2%             |
| Quality of life (EQ-5D-5L)                            |                |              |         |               |                |              |         |                  |
| Index score (range: −0.864–1)                         | 0.8 (0.2)      | 0.9 (0.2)    | 0.001   | 0.81 (0.20)   | 0.8 (0.2)      | 0.9 (0.2)    | <0.001  | 0.81 (0.2)       |
| Visual Analogue Scale (0–100)                         | 66.0 (15.3)    | 69.6 (13.4)  | <0.001  | 67.1 (14.8)   | 66.0 (15.4)    | 69.4 (13.3)  | 0.001   | 67.6 (14.6)      |
| Healthcare utilisation in the past year               |                |              |         |               |                |              |         |                  |
| Hospitalisation frequency                             | 0.453          | 0.557        |         |               | 0.585          | 0.660        |         |                  |
| 0                                                    | 83.8%          | 81.2%        |         | 83.0%         | 83.6%          | 82.0%        |         | 82.9%            |
| 1–2                                                  | 14.4%          | 17.3%        |         | 15.2%         | 14.0%          | 16.7%        |         | 15.3%            |
| 2+                                                   | 1.9%           | 1.5%         |         | 1.8%          | 2.4%           | 1.3%         |         | 1.9%             |
| Hospitalisation Length (days, mean, SD) (n=1073)      | 1.1 (5.1)      | 1.5 (8.2)    | 0.424   | 1.2 (6.2)     | 1.1 (5.1)      | 1.4 (8.3)    | 0.535   | 1.2 (6.8)        |
| Specialist outpatient clinics                         | 69.0%          | 70.7%        | 0.587   | 69.5%         | 68.8%          | 70.2%        | 0.636   | 69.5%            |
| General outpatient clinics                            | 89.6%          | 94.1%        | 0.018   | 91.0%         | 89.8%          | 94.3%        | 0.007   | 92.0%            |
| Elderly day care service                              | 9.4%           | 9.9%         | 0.824   | 9.6%          | 10.2%          | 9.1%         | 0.554   | 9.6%             |
| Cost (out of pocket) (HKD) median (IQR, IQR) (n=1063) | 1000 (0–3000)  | 1000 (0–2000)| 0.141   | 1000 (0–3000) | 1000 (0–2000) | 1000 (0–2000)| 0.488   | 1000 (0–3000)    |
| Physical examinations                                 |                |              |         |               |                |              |         |                  |
| Blood pressure                                       |                |              |         |               |                |              |         |                  |
| Systolic (mean, SD)                                   | 133.2 (15.6)   | 134.2 (15.9) | 0.337   | 133.5 (15.7)  | 133.5 (15.6)   | 133.3 (15.2) | 0.848   | 133.4 (15.8)     |
| Diastolic (mean, SD)                                  | 74.9 (8.6)     | 78.4 (10.0)  | <0.001  | 75.9 (9.9)    | 74.1 (10.0)    | 78.6 (9.9)   | <0.001  | 76.2 (10.2)      |
| Normal (SBP <120 and DBP <80)                         | 19.2%          | 14.8%        | 0.272   | 17.9%         | 19.9%          | 15.8%        | 0.070   | 17.9%            |
| Prehypertension (SBP: 120–139 or DBP: 80–89)         | 45.8%          | 48.2%        |         | 46.5%         | 44.6%          | 48.4%        |         | 46.4%            |
| Stage I hypertension (SBP: 140–159 or DBP: 90–99)     | 30.2%          | 30.6%        |         | 30.3%         | 29.9%          | 29.8%        |         | 29.8%            |
| Stage II hypertension (SBP ≥160 or DBP ≥100)         | 4.8%           | 6.5%         |         | 5.3%          | 5.6%           | 6.0%         |         | 5.8%             |
| Pulse (per minute)                                    | 71.5 (19.5)    | 75.2 (28.0)  | 0.016   | 72.7 (22.5)   | 71.7 (22.0)    | 74.9 (24.8)  | 0.041   | 73.2 (23.4)      |
| Weight (kg, mean, SD)                                 | 57.5 (56.8)    | 66.5 (9.6)   | <0.001  | 60.2 (10.4)   | 56.9 (9.3)     | 66.9 (9.7)   | <0.001  | 61.6 (10.7)      |
| Height (cm, mean, SD)                                 | 154.0 (6.2)    | 165.5 (6.7)  | <0.001  | 157.4 (8.2)   | 153.4 (6.2)    | 165.6 (6.7)  | <0.001  | 159.2 (8.8)      |
| Waist circumference (cm, mean, SD)                    | 88.8 (9.7)     | 93.2 (9.5)   | <0.001  | 90.2 (9.9)    | 89.1 (9.9)     | 93.2 (9.2)   | <0.001  | 91.1 (9.8)       |
Table 2  Continued

| Characteristics                     | Unweighted rates and analyses | Weighted rates and analyses |
|-------------------------------------|------------------------------|-----------------------------|
|                                     | Female (n=753) | Male (n=324) | P value | Female (n=568) | Male (n=508) | P value | Weighted total % |
| Body mass index (mean, SD)          |                |              |         |                |              |         |                   |
| Underweight (<18.5)                 | 24.2 (3.8)     | 24.2 (2.0)   | 0.963   | 24.2 (3.7)     | 24.4 (3.1)   | 0.398   | 24.3 (3.4)        |
| Normal (18.5–22.9)                  | 37.6%          | 31.3%        | 0.067   | 37.9%          | 31.5%        | 0.013   | 35.4%             |
| Overweight (23–24.9)                | 20.4%          | 26.0%        | 0.22    | 20.5%          | 23.6%        | 0.22    | 22.0%             |
| Obese (≥25)                         | 37.9%          | 39.9%        | 0.38    | 37.0%          | 42.2%        | 0.38    | 39.5%             |
| Handgrip strength (kg)§§            |                |              |         |                |              |         |                   |
| <Cut-off score (<26 for male, <18 for female) | 36.3%          | 36.1%        | 0.964   | 36.2%          | 34.7%        | 0.061   | 37.6%             |
| Left hand (mean, SD)                | 17.4 (4.2)     | 26.4 (7.0)   | 20.1 (6.6) | 17.0 (4.2)     | 26.7 (7.0)   | 21.5 (7.5) |
| Right hand (mean, SD)               | 18.5 (4.3)     | 27.4 (7.5)   | 21.1 (6.8) | 18.0 (4.3)     | 27.5 (7.7)   | 22.5 (7.7) |
| Both hand (mean, SD)                | 19.1 (4.1)     | 28.5 (7.1)   | 21.9 (6.7) | 18.6 (4.0)     | 28.8 (7.2)   | 23.4 (7.6) |

Statistical methods: X² tests were used for categorical data; paired t-tests were used for continuous data.

* n=136, those who did not drink alcohol the past 12 months were regarded as 0 in AUDIT-C.
† 719 patients were assessed with ISI.
‡ Only those who had one or more pain areas in the past 3 months were assessed with BPI or PASE-C.
§ Measured by the 5-item Sarcopenia Assessment which were added at a later stage.
¶ HK-MoCA replaced AMIC in a later stage.
** Mean (SD) was for 203 patients who did PHQ-9. The % was for all the 1077 patients with the rest 874 patients who screened negative in PHQ-2 regarded as having normal scores in PHQ-9.
†† Mean (SD) was for 182 patients who did GAD-7. The % was for all the 1077 patients with the rest 895 patients who screened negative in GAD-2 regarded as having normal scores in GAD-7.
‡‡ Only those who had social media use in the past 2 weeks were assessed.
§§ Better result of two series for left or right hand, or best result of both hands.
AUDIT-C, the 3-item Alcohol Use Disorders Identification Test-consumption; DBP, diastolic blood pressure; ENT, ear, nose and throat; EQ-5D-5L, EuroQol-5-Dimensions-5-Level; GAD-2, the two-item General Anxiety Disorder scale; HKD, Hong Kong Dollars; HK-MoCA, Montreal Cognitive Assessment Hong Kong version; ISI, 7-item Insomnia Severity Index; PHQ-2, the two item Patient Health Questionnaire for depression; SBP, systolic blood pressure.
of two trials of both hands) below the cut-off point, 12% needed help or were dependent in at least one out of the five daily functions (using telephone, transportation, shopping, preparing meals or financial management). Overall, 30%, 59% and 11% of patients rated their health being ‘excellent/very good/good’, ‘fair’ or ‘poor’, respectively. Seventy-three per cent reported the presence of one (21%) or two or more (52%) body pain areas, 17% scored the HK-MoCA <22 suggesting at least mild cognitive impairment; 18% had PHQ-2 ≥3, while 17% had PHQ-9 ≥5 suggesting mild depression or more severe; 15% had GAD-2 ≥3, while 16% had GAD-7 ≥5 suggesting mild anxiety or more severe; 50% had insomnia at subthreshold level or above, the mean score of the meaning of existence was 4.9 (SD=1.2) out of 7, 28% reported feeling lonely. More finding details can be seen in table 2. More female patients had incontinence, pain, sarcopenia and cognitive impairment than male patients. Female patients were more likely to be screened positive in depression and anxiety, reported severer level of insomnia and reported lower perceived existence of meaning than male patients. Female patients were more likely to be frail. More male patients used social media (p<0.05). The loneliness level and perceived social support were not significantly different between female and male patients.
In addition, after weighting, the EQ-5D-5L index score was 0.81 (0.20) and its Visual Analogue Scale score was 67.6 (14.6) out of 100. Female patients showed poorer quality of life. In the last year, 17% were admitted to hospital, 92% attended GOPC, 70% attended SOPC, 10% used elderly day care centre services and the median out-of-pocket health cost was HK$1000 (US$150) for any health expenditures not covered by the public health system or insurance. Male patients reported more GOPC visits than female patients in the past year (p=0.007).

Future plans
The patients will be followed up regularly (interval of ~2 years) to monitor changes in health status and outcomes through data collected from questionnaires, physical assessments and clinical records. Key biopsychosocial assessments such as depression, anxiety, loneliness, pain, frailty, as well as quality of life would be included in the follow-up assessments, but each follow-up might be added with some additional assessments with specific research interests. The first follow-up (ie, wave 2 assessment) had started in early 2018. Additional information on mobility by the 30s chair-stand test, visual acuity by Amsler Grid test and hearing by Weber’s test and Rinne Test were added. Information on electronic medical records will also be updated to provide information on health service utilisation, changes in medication use and new onset of diseases and death.

The longitudinal trajectories of biopsychosocial health profiles of these primary care patients will be described. For example, changes and occurrence of different
Strengths and limitations
This study has several strengths. First, this is one of the few aetiological studies on older adults being conducted in Asian primary care settings to examine physical, psychological and social problems accompanying with multimorbidity. Second, it prospectively covers a range of biopsychosocial factors, which are not included in other previous large-scale studies since plenty of them are derived from extracted medical or insurance records. Our findings suggest that people with multimorbidity have significant complex healthcare needs in physical, mental and social aspects such as obesity, multiple body pain, polypharmacy, depression, anxiety, insomnia and loneliness. The results suggested that a holistic approach that addresses general physical and functional domain of health, at the same time assessing and managing psychological and social problems is therefore needed in the care of older adults with multimorbidity. Services which are designed to cater for the complex needs of elderly patients with multimorbidity from biopsychosocial perspectives are urgently needed. These service models should also be adapted and tested in local circumstances to maximise its efficacy. Furthermore, given the significant differences found between male and female patients in biopsychosocial aspects, future interventions may also need to take gender differences into account. Third, the results were weighted according to the census data to make the sample more representative of the general population. In general, the weighted results were similar to the unweighted results, and in consistency with results reported in the western populations. Fourth, because it contains linked electronic medical records, it will allow us to follow them up for public medical service use and mortality.

There are also several limitations. First, self-selection bias might still exist which was consistent with other similar studies, although we used weighting for adjustment, as not all variables were available for weighting such as education. Since only ambulatory adults who agreed to join were recruited and these usually are more likely to be female and those with higher educational level and higher self-motivation, and those who were housebound or institutionalised are less likely to have been included, we might have resulted in a relatively healthier and higher-functioning patients in primary care, and the real health status might be worse than what are reported in our study. Future studies may need to take measures to increase participation from male and vulnerable patients. Second, the sample size may limit examinations of potential interactions and factors associated with multimorbidity in some subgroups such as older men and patients with lower educational levels, or uncommon health problems. Third, we used a two-step assessment for some health indicators. While false negative reported rates of pain, insomnia and alcohol use were unlikely, there might be false negative rates for depression and anxiety as the specificity and sensitivity of PHQ-2 and GAD-2 were not 100% (although results from meta-analytical reviews suggest they are reasonable to use in initial screening). In addition, as PHQ-2 and GAD-2 are often used for screening with results in dichotomies (negative/positive), this might limit application of some statistical analysis such as using growth models in future longitudinal data. Fourth, for a few assessments, we only conducted them among a subgroup of participants, for example, PASE for physical activity among those patients with pain. Furthermore, some additional assessments such as meaning, sarcopenia, oral health were added at a later stage. So only subgroup data could be reported in this paper or analysed in the future when using these data.

Acknowledgements We would like to thank the General Outpatient Clinics (Lek Yuen, Ma On Shan, Shatin (Tai Wai), Yuen Chau Kok) and Shatin Rhenish Neighbourhood Elderly Centre for the support and help in recruitment. We also greatly thank all the patients who joined in the cohort.

Contributors SYSW conceived and supervised the study and revised the manuscript. DZ contributed to study design, analysed the data, prepared the draft and revised the manuscript. RWSS and CW contributed to the study design and implementation, and manuscript revisions. DZ contributed to data collection and manuscript revisions. SWM and MJC contributed to manuscript revisions.

Funding The staff working on this cohort received funding from the Hong Kong Jockey Club Charities Trust.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request. The authors warmly welcome collaborations for future research based on this study. For those who would like to request for the data or propose new assessments into the follow-up assessments, they can email to: yeungshanwong@cuhk.edu.hk. For more information please see the website: http://cccp.sphpc.cuhk.edu.hk/chi/.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Dexing Zhang http://orcid.org/0000-0003-0073-4752
Regina Wing Shan Sit http://orcid.org/0000-0002-4717-7773
Marjorie C Johnston http://orcid.org/0000-0002-4660-3099

REFERENCES
1 Uijen AA, van de Lisdonk EH. Multimorbidity in primary care: prevalence and trend over the last 20 years. Eur J Gen Pract 2008;14:28–32.
2 Koné Pefoyo AJ, Bronskill SE, Gruneir A, et al. The increasing burden and complexity of multimorbidity. BMC Public Health 2015;15:415.
3 Violan C, Foguet-Boreu Q, Flores-Mateo G, et al. Prevalence, determinants and patterns of multimorbidity in primary care: a systematic review of observational studies. PLoS One 2014;9:e102149.
28 Bretschneider C, Leicht H, Bickel H, et al. Relation of Multimorbidity on health-related quality of life - translation of the EQ-5D-5L to the multiCare cohort study. PLoS One 2013;8:e66742.

29 Mercer SW, Gunn J, Wyke S. Improving the health of people with multimorbidity: the need for prospective cohort studies. London, England: SAGE Publications Sage UK, 2011.

30 France EF, Wyke S, Gunn JM, et al. Multimorbidity in primary care: a systematic review of prospective cohort studies. Br J Gen Pract 2012;62:e297–307.

31 Kuo RN, Lai M-S. The influence of socio-economic status and multimorbidity patterns on healthcare costs: a six-year follow-up under a universal healthcare system. Int J Equity Health 2013;12:69.

32 Gu J, Chao J, Chen W, et al. Multimorbidity and health-related quality of life among the community-dwelling elderly: a longitudinal study. PLoS One 2018;13(7):e0199154.

33 Tromp J, Tay WT, Ouwerkerk W, et al. Multimorbidity in patients with heart failure from 11 Asian regions: a prospective cohort study using the ASIAN-HF registry .3 2018; 15: e1002541.

34 Hughes LD, McMurdo MET, Guthrie B. Guidelines for people not for diseases: the challenges of applying UK clinical guidelines to people with multimorbidity. Age Ageing 2013;42:62–9.

35 Muth C, Beyer M, Fortin M, et al. Multimorbidity’s research challenges and priorities from a clinical perspective: the case of ‘Mr Curran’. Eur J Gen Pract 2014;20:139–47.

36 Fortin M, Lapointe L, Hudson C, et al. Multimorbidity is common to family practice: is it commonly researched? Can Fam Physician 2005;51:244–5.

37 Kadam U. Redesigning the general practice consultation to improve care for patients with multimorbidity. BMJ 2012;345:e6202.

38 Smith SM, Soubhi H, Fortin M, et al. Managing patients with multimorbidity: systematic review of interventions in primary care and community settings. BMJ 2012;345:e6205.

39 Wallace E, Salisbury C, Guthrie B, et al. Managing patients with multimorbidity in primary care. BMJ 2015;350:h176.

40 The Government of Hong Kong Special Administrative Region (HK SAR). 2016 population By-census, 2018. Available: http://www.bycensus2016.gov.hk/en/bc-mthtml [Accessed 31 Jul 2018].

41 Centre for Health Protection, Department of Health, The Government of the Hong Kong Special Administrative Region. Life Expectancy at Birth (Male and Female), 1971 - 2017, 2018. Available: https://www.chp.gov.hk/en/statistics/data/10/27/111html [Accessed 23 Jul 2018].

42 Hospital Authority, HK SAR. Hospital authority annual report 2016-2017. Available: http://www.ha.org.hk/ho/corpcomm/AR201617/ebook/en/mobile/index.html#l [Accessed 23 Jul 2018].

43 Rosner B. Fundamentals of biostatistics. 6th edn. Pacific Grove, CA: Brooks/Cole, 2006.

44 Levine M, Ensom MHH. Post hoc power analysis: an idea whose time has passed?. Pharmacotherapy 2001;21:405–9.

45 Wang HHH, Wang JJ, Wong SYS, et al. Epidemiology of multimorbidity in China and implications for the healthcare system: a cross-sectional survey among 162,464 community-dwelling residents in southern China. BMC Med 2014;12:168.

46 Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 2012;380:37–43.

47 Yu X, Stewart SM, Wong PTK, et al. Screening for depression with the patient health Questionnaire-2 (PHQ-2) among the general population in Hong Kong. J Affect Disord 2011;134:444–7.

48 Yu X, Tam WWS, Wong PTK, et al. The patient health Questionnaire-9 for measuring depressive symptoms among the general population in Hong Kong. Compr Psychiatry 2012;53:95–102.

49 Plummer F, Manea L, Trepel D, et al. Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic meta-analysis. Gen Hosp Psychiatry 2016;39:24–31.

50 Leung GTY, de Jong Gierveld J, Lam LCM. Validation of the Chinese translation of the 6-item Jong Gierveld loneliness scale in elderly Chinese. Int J Psychogeriatr 2008;20:1262–72.

51 Yu DSF, Doris S. Insomnia severity index: psychometric properties with Chinese community-dwelling older people. J Adv Nurs 2010;66:2350–9.

52 Nga SPC, Cheung RTH, Lam PL, et al. Validation and reliability of the physical activity scale for the elderly population in the Chinese elderly. J Rehabil Med 2012;44:462–5.

53 Rolffsen DB, Majumdar SR, Tsuyuki RT, et al. Validity and reliability of the Edmonton frail scale. Age Ageing 2006;35:526–9.

54 Zhang D, Chan DCC, Ng RTF, et al. Meaning and its association with happiness, health and healthcare utilization: a cross-sectional study. J Affect Disord 2018;227:795–802.

Zhang D, et al. BMJ Open 2020;10:e022797. doi:10.1136/bmjopen-2018-022797
55 Malmstrom TK, Morley JE. SARC-F: a simple questionnaire to rapidly diagnose sarcopenia. *J Am Med Dir Assoc* 2013;14:531–2.

56 Woo J, Leung J, Morley JE. Validating the SARC-F: a suitable community screening tool for sarcopenia? *J Am Med Dir Assoc* 2014;15:630–4.

57 Wong A, Xiong YY, Kwan PWL, et al. The validity, reliability and clinical utility of the Hong Kong Montreal cognitive assessment (HK-MoCA) in patients with cerebral small vessel disease. *Dement Geriatr Cogn Disord* 2009;28:81–7.

58 Wong ELY, Ramos-Goñi JM, Cheung AWL, et al. Assessing the use of a feedback module to model EQ-5D-5L health states values in Hong Kong. *Patient* 2018;11:235–47.

59 Silva Junior SHA, Santos SM, Coeli CM, et al. Assessment of participation bias in cohort studies: systematic review and meta-regression analysis. *Cad Saúde Pública* 2015;31:2259–74.

60 Mitchell AJ, Yadegarfar M, Gill J, et al. Case finding and screening clinical utility of the patient health questionnaire (PHQ-9 and PHQ-2) for depression in primary care: a diagnostic meta-analysis of 40 studies. *BJPsych Open* 2016;2:127–38.